• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝移植后新发恶性肿瘤:晚期死亡的主要原因。

De novo malignancies after liver transplantation: a major cause of late death.

作者信息

Fung J J, Jain A, Kwak E J, Kusne S, Dvorchik I, Eghtesad B

机构信息

Division of Transplantation Surgery, The Thomas E. Starzl Transplantation Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.

出版信息

Liver Transpl. 2001 Nov;7(11 Suppl 1):S109-18. doi: 10.1053/jlts.2001.28645.

DOI:10.1053/jlts.2001.28645
PMID:11689783
Abstract
  1. Recurrent and de novo malignancies are the second leading causes of late death in liver transplant recipients, following age-related cardiovascular complications. 2. The increased incidence of de novo malignancies in liver transplant recipients compared with the general population reflects their demographic makeup, known preexistent risk factors for cancer, greater rate of chronic viral infection, and actions of exogenous immunosuppression. 3. The greatest incidence of de novo malignancies is seen in cancers associated with chronic viral infections, such as Epstein-Barr virus-associated posttransplant lymphoproliferative disease, and skin cancers, including squamous cell carcinoma and Kaposi's sarcoma. 4. Although a greater incidence of such malignancies as oropharyngeal malignancy and colorectal cancer was noted, there did not appear to be an increased risk for liver transplant recipients matched for age, sex, and length of follow-up using modified life-table technique and Surveillance Epidemiology End Result data with a similar at-risk group. However, they may present with more advanced stages of disease. 5. An increased incidence of de novo cancers in chronically immunocompromised liver transplant recipients demands careful long-term screening protocols to help facilitate diagnosis at an earlier stage of disease.
摘要
  1. 复发和新发恶性肿瘤是肝移植受者晚期死亡的第二大主要原因,仅次于与年龄相关的心血管并发症。2. 与普通人群相比,肝移植受者新发恶性肿瘤的发病率增加,这反映了他们的人口构成、已知的癌症既往危险因素、更高的慢性病毒感染率以及外源性免疫抑制的作用。3. 新发恶性肿瘤的最高发病率见于与慢性病毒感染相关的癌症,如爱泼斯坦-巴尔病毒相关的移植后淋巴细胞增生性疾病,以及皮肤癌,包括鳞状细胞癌和卡波西肉瘤。4. 尽管观察到口咽恶性肿瘤和结直肠癌等此类恶性肿瘤的发病率较高,但对于使用改良生命表技术和监测流行病学最终结果数据、与类似风险组进行年龄、性别和随访时间匹配的肝移植受者,似乎并未增加风险。然而,他们可能表现为疾病的更晚期阶段。5. 慢性免疫功能低下的肝移植受者新发癌症发病率增加,需要仔细的长期筛查方案,以帮助在疾病早期阶段促进诊断。

相似文献

1
De novo malignancies after liver transplantation: a major cause of late death.肝移植后新发恶性肿瘤:晚期死亡的主要原因。
Liver Transpl. 2001 Nov;7(11 Suppl 1):S109-18. doi: 10.1053/jlts.2001.28645.
2
De novo malignancies following liver transplantation: impact and recommendations.肝移植后新发恶性肿瘤:影响和建议。
Liver Transpl. 2009 Nov;15 Suppl 2:S90-4. doi: 10.1002/lt.21898.
3
De novo malignancies after kidney and liver transplantations: experience on 582 consecutive cases.肾移植和肝移植后的新发恶性肿瘤:582例连续病例的经验
Transplant Proc. 2006 May;38(4):1135-7. doi: 10.1016/j.transproceed.2006.02.016.
4
De novo cancers and post-transplant lymphoproliferative disorder in adult liver transplantation.成人肝移植中的新发癌症及移植后淋巴细胞增生性疾病
Pathol Int. 2006 Nov;56(11):712-5. doi: 10.1111/j.1440-1827.2006.02035.x.
5
Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation.肝移植患者中基于移植前病因的移植后恶性肿瘤差异风险证据。
Liver Transpl. 2002 May;8(5):482-7. doi: 10.1053/jlts.2002.32977.
6
Colorectal cancer after orthotopic liver transplantation.原位肝移植术后的结直肠癌
Crit Rev Oncol Hematol. 2005 Oct;56(1):147-53. doi: 10.1016/j.critrevonc.2004.12.013.
7
Comparison of de novo tumours after liver transplantation with incidence rates from Italian cancer registries.肝移植后新发肿瘤与意大利癌症登记处发病率的比较。
Dig Liver Dis. 2010 Jan;42(1):55-60. doi: 10.1016/j.dld.2009.04.017. Epub 2009 Jun 3.
8
De novo tumors after liver transplantation: a single-institution experience.肝移植后的新发肿瘤:单中心经验
Liver Transpl. 2002 Mar;8(3):285-91. doi: 10.1053/jlts.2002.29350.
9
Liver transplant recipients are not at increased risk for nonlymphoid solid organ tumors.肝移植受者发生非淋巴样实体器官肿瘤的风险并未增加。
Cancer. 1998 Sep 15;83(6):1237-43.
10
Cancer incidence after immunosuppressive treatment following kidney transplantation.肾移植后免疫抑制治疗后的癌症发病率。
Crit Rev Oncol Hematol. 2005 Oct;56(1):71-85. doi: 10.1016/j.critrevonc.2004.11.010.

引用本文的文献

1
Incidence, screening, and management of malignancies in liver transplant patients: A review.肝移植患者恶性肿瘤的发病率、筛查与管理:综述
World J Transplant. 2025 Sep 18;15(3):101046. doi: 10.5500/wjt.v15.i3.101046.
2
Appropriate Timing and Interval for Surveillance Colonoscopy after Liver Transplantation Based on a Single-Centre Experience.基于单中心经验的肝移植术后监测结肠镜检查的合适时机和间隔
Can Liver J. 2025 Feb 25;8(1):39-48. doi: 10.3138/canlivj-2024-0041. eCollection 2025 Feb.
3
Clinical outcomes of gastric cancer surgery after liver transplantation.
肝移植术后胃癌手术的临床结局
Ann Surg Treat Res. 2023 Feb;104(2):101-108. doi: 10.4174/astr.2023.104.2.101. Epub 2023 Jan 31.
4
Successful pancreatoduodenectomy of duodenal malignancy after orthotopic liver transplantation: A case report.原位肝移植术后十二指肠恶性肿瘤成功实施胰十二指肠切除术:一例报告。
Front Surg. 2023 Jan 6;9:1068215. doi: 10.3389/fsurg.2022.1068215. eCollection 2022.
5
Annual Meeting of the Canadian Association for the Study of the Liver (CASL), the Canadian Network on Hepatitis C (CANHEPC) and the Canadian Association of Hepatology Nurses (CAHN) 2021 Abstracts.加拿大肝脏研究协会(CASL)、加拿大丙型肝炎网络(CANHEPC)和加拿大肝病护理协会(CAHN)2021年年会摘要
Can Liver J. 2021 Apr 29;4(2):113-248. doi: 10.3138/canlivj.4.2.abst. eCollection 2021 Spring.
6
The Spectrum of Malignant Neoplasms among Liver Transplant Recipients: Sociodemographic Factors, Mortality, and Hospital Burden.肝移植受者恶性肿瘤谱:社会人口学因素、死亡率和医院负担。
Int J Med Sci. 2022 Jan 9;19(2):299-309. doi: 10.7150/ijms.66533. eCollection 2022.
7
Pancreatic adenocarcinoma in liver transplant recipients: a case series.肝移植受者的胰腺腺癌:病例系列
Ann Pancreat Cancer. 2021 Oct;4. doi: 10.21037/apc-21-4. Epub 2021 Oct 30.
8
Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation.芦可替尼用于肝移植术后真性红细胞增多症和骨髓纤维化患者的治疗。
Clin Case Rep. 2021 Sep 5;9(9):e04782. doi: 10.1002/ccr3.4782. eCollection 2021 Sep.
9
Cervical dysplasia after renal transplantation: A retrospective cohort study.肾移植术后宫颈发育异常:一项回顾性队列研究。
Turk J Obstet Gynecol. 2021 Mar 12;18(1):7-14. doi: 10.4274/tjod.galenos.2021.28938.
10
malignancies after liver transplantation: The effect of immunosuppression-personal data and review of literature.肝移植后的恶性肿瘤:免疫抑制的影响——个人数据和文献回顾。
World J Gastroenterol. 2019 Sep 21;25(35):5356-5375. doi: 10.3748/wjg.v25.i35.5356.